Uncomplicated vivax malaria Infections and Infestations Uncomplicated vivax malaria
Conditions
Interventions
Dihydroartemisinin-piperaquine versus Chloroquine treatment.
Sponsors
University of Oxford (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males and Females aged over 12 months 2. Body weight more 5 kg 3. Microscopically confirmed, mono-infection of Plasmodium vivax (parasitaemia more than or equal to 5/500 White Blood Cells [WBC]) 4. Fever (axillary temperature more than or equal to 37.5°C) OR history of fever 5. Informed consent obtained by patients and in the case of children, by parents or guardians 6. Willingness and ability to comply with the study protocol
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity to the study drugs 2. Presence of intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study 3. Pregnancy or lactation, urine test for beta human Chorionic Gonadotropin (beta-hCG) to be performed on any woman of child bearing age 4. Mefloquine treatment in the previous 60 days 5. Dapsone Pyrimethamine (DP) treatment in the previous three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Day 63 cure | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Thailand
Outcome results
None listed